公开(公告)号：US20130210157A1

公开(公告)日：2013-08-15

申请号：US13744237

申请日：2013-01-17

Applicant: The Board of Regents of the University of Texas System

Inventor： Banglin CHEN ,  Shengchang XIANG

IPC: C07F19/00 ,  B01J20/22

CPC classification number: C07F19/005 ,  B01D53/02 ,  B01D2253/204 ,  B01D2257/504 ,  B01J20/226 ,  C07F3/003 ,  F17C11/005 ,  G01N31/22 ,  Y02C10/08 ,  Y02P20/152

Abstract: Disclosed herein are mixed metal-organic frameworks, Zn3(BDC)3[Cu(SalPycy)] and Zn3(CDC)3[Cu(SalPycy)], wherein BDC is 1,4-benzenedicarboxylate, CDC is 1,4-cyclohexanedicarboxylate, and SalPyCy is a ligand of the formula: These are useful for applications such as selective gas storage, selective molecular separations, and selective detection of molecules, including enantioselective applications thereof.

Abstract translation: 本文公开了混合的金属 - 有机骨架，Zn3（BDC）3 [Cu（SalPycy）]和Zn3（CDC）3 [Cu（SalPycy）]，其中BDC是1,4-苯二甲酸酯，CDC是1,4-环己烷二羧酸酯， SalPyCy是下式的配体：它们可用于诸如选择性气体储存，选择性分子分离和选择性检测分子（包括其对映选择性应用）的应用。

公开(公告)号：US20130150308A1

公开(公告)日：2013-06-13

申请号：US13770416

申请日：2013-02-19

Applicant: The Board of Regents of The University of Texas System

Inventor： Nancy MONSON

IPC: C12Q1/68

CPC classification number: C12Q1/686 ,  A61K38/02 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/6896

Abstract: The present invention provides for the diagnosis and prediction of multiple sclerosis (MS) in subject utilizing a unique a codon signature in VH4 expressiong B cells that has now been associated with MS and not with any other autoimmune disease.

Abstract translation: 本发明提供了本发明的多发性硬化症（MS）的诊断和预测，其利用了现在已经与MS相关的VH4表达B细胞中的独特的密码子特征，而不与任何其他自身免疫疾病相关。

公开(公告)号：US12252464B2

公开(公告)日：2025-03-18

申请号：US18315446

申请日：2023-05-10

Applicant: The Board of Regents of The University of Texas System

Inventor： Daniel J. Siegwart ,  Jason B. Miller

IPC: C07C311/32 ,  A61K47/54 ,  A61K47/69 ,  A61K48/00 ,  B82Y5/00 ,  C07C229/06 ,  C07C309/14 ,  C07F9/09 ,  C07F9/10 ,  C12N15/11 ,  C12N15/113 ,  C12N15/88

Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.

公开(公告)号：US20250064752A1

公开(公告)日：2025-02-27

申请号：US18930467

申请日：2024-10-29

Applicant: The Board of Regents of The University of Texas System

Inventor： Daniel J. SIEGWART ,  Philip J. THOMAS ,  Arthur E. JOHNSON ,  Michael J. TORRES ,  Jason B. MILLER

IPC: A61K9/51 ,  A61K48/00 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113

Abstract: In some aspects, the present disclosure provides a nanoparticle composition comprising tRNA and an aminolipid delivery compound. The aminolipid delivery compound may be a dendrimer, dendron, or dendritic lipid, a polymer such as a polyamide or polyester, or a lipid with one or more hydrophobic components. In some embodiments, these compositions may be administered to a patient to treat a genetic disease or disorder such as cystic fibrosis, Duchene muscular dystrophy, or cancer.

公开(公告)号：US12234516B2

公开(公告)日：2025-02-25

申请号：US17206895

申请日：2021-03-19

Applicant: The Board of Regents of the University of Texas System

Inventor： Min Soo Kim ,  James Brugarolas ,  Tae Hyun Hwang ,  Yang Xie

IPC: C12Q1/6886 ,  A61P35/00 ,  C12N15/52 ,  C40B40/08 ,  G01N33/50 ,  G16B25/00 ,  G16B25/10 ,  G16B25/20 ,  G16B30/00 ,  G16H50/20 ,  G16H50/30

Abstract: Described herein are methods and systems for identifying and/or treating subjects having cancer who are more likely to respond to treatment with an inhibitor of the transcription factor HIF-2α.

公开(公告)号：US20250019465A1

公开(公告)日：2025-01-16

申请号：US18709365

申请日：2022-11-14

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Kiyoshi ARIIZUMI ,  Jin-Sung CHUNG ,  Ponciano D. CRUZ, Jr.

IPC: C07K16/44 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30

Abstract: Provided herein are single domain antibodies (sdAbs) having a specific affinity for a rare heparan sulfate moiety which can be used to disrupt DC-HIL function to reduce and prevent cancer progression and metastasis. Compositions and methods of use thereof are also provided for use of these sdAbs to treat cancer and cancer metastasis in a subject in need thereof.

公开(公告)号：US20250011791A1

公开(公告)日：2025-01-09

申请号：US18709305

申请日：2022-11-17

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Berge A. MINASSIAN ,  Emrah GUMUSGOZ ,  Mayank VERMA

IPC: C12N15/113 ,  A61P3/00 ,  A61P25/28 ,  C12N15/86

Abstract: The present disclosure provides methods and compositions for the treatment of glycogen storage disorders, such as, for example, Lafora Disease and adult polyglucosan body disease. The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for artificial micro RNAs (amiRNAs) directed against GYS1.

公开(公告)号：US20250009750A1

公开(公告)日：2025-01-09

申请号：US18666636

申请日：2024-05-16

Applicant: The Board of Regents of the University of Texas System

Inventor： Eloise Dray ,  Stanton F. McHardy

IPC: A61K31/517 ,  A61P35/00

Abstract: The present disclosure is concerned with methods of treating disorders associated with overexpression of an eyes absent (EYA) protein such as, for example, vascular disease, a fibrosis-related disorder, hearing loss, and a metabolic disease using quinazoline-2,4-diamines. Also disclosed are methods of treating cancer that comprises a tumor that overexpresses at least one eyes absent (EYA) protein (e.g., breast cancer, cervical cancer, ovarian cancer, liver cancer, pancreatic cancer, pediatric cancers). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：USD1056217S1

公开(公告)日：2024-12-31

申请号：US29862682

申请日：2022-12-12

Applicant: The Board of Regents of The University of Texas System

Designer： Kenneth Dale Westover

公开(公告)号：US12181555B2

公开(公告)日：2024-12-31

申请号：US18425964

申请日：2024-01-29

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Darin Okuda

IPC: G01R33/56 ,  G01R33/48 ,  G06N20/00 ,  G06T7/11

Abstract: 3D MRI images of the brain may be created and acquired. After administration of contrast, brain lesions and other abnormalities may be identified and isolated from the 3D MRI images, with each lesion serving as a region of interest (ROI). 3D region of contrast enhancement images may be created from segmented 3D MRI images and different regions of contrast enhancement of the brain lesion may be depicted. Saved regions of contrast enhancement may be converted into stereolithography format, maximum intensity projection (MIP) images, and/or orthographic projection images. Data corresponding to these resulting 3D region of contrast enhancement images may be used to create 3D printed models of the isolated region of contrast enhancement. Analysis of the 3D brain region of contrast enhancement images and the 3D printed region of contrast enhancement models may enable a more efficient and accurate way of determining brain lesion risk factors and effective treatment regimens.